Debate Over Proposed Access to Unapproved Peptides Highlights Safety Concerns
Scientists and regulators warn that experimental peptides lack FDA approval and robust clinical data, while a White House proposal seeks to allow pharmacies to sell them, sparking controversy over safety and ethics.
A temporary access policy posted on a White House docket on Oct. 14 would permit licensed pharmacies to compound and sell certain unapproved peptides to consumers. The Food and Drug Administration’s scientists advised against the measure, citing insufficient clinical testing, but an FDA advisory panel voted to relax restrictions. Several panel members are recent appointees with financial interests in the peptide market, and the Department of Health and Human Services confirmed that each member meets the agency’s ethics standards.
"I voted 'yes' for patient safety, the greater good and medical freedom," said Haleem Mohammed, chief medical officer of a men’s health clinic that sells peptides, during the advisory meeting.
Critics note that peptides are often marketed as natural and safe, yet many have not been demonstrated to be effective or non-toxic in humans. Researchers point out that substances such as insulin become drugs when administered for therapeutic purposes, and the same classification applies to peptides used to treat or prevent conditions. Stanford peptide scientist Katrin Svensson emphasized that natural origin does not guarantee safety, citing examples of toxicity from overdosing on insulin.
Claims that experimental peptides can treat a range of ailments—including reflux disease, neurologic disorders, muscle injuries, and COVID-19—remain unsupported by rigorous trials. Small studies cited by promoters lack control groups or detailed methodology, and FDA reviewers have described the available evidence as inadequate. Physical rehabilitation doctor Flynn McGuire warned that anecdotal reports of rapid recovery are unreliable and that “medicine and science just don’t work fast.”
Another misconception addressed is that peptides cannot be patented. Legal scholar Jacob Sherkow explained that while natural peptides themselves are not patentable, modified formulations and delivery methods can be, and hundreds of peptide patents already exist. The market potential for peptide-based drugs, such as GLP-1 analogues, is projected to reach billions of dollars.
Health-policy advocates, including Health Secretary Robert F. Kennedy Jr., argue that the United States lags behind peer nations in health outcomes and that drug costs burden many Americans. However, researchers caution that expanding access to unapproved peptides without completing clinical trials could undermine safety and public health.
The pharmaceutical trade group PhRMA has urged the FDA to maintain current restrictions, warning that easing them would diminish incentives for companies to invest in the costly trials required for approval.